0013 (0013) Fair Value & Analysis

Healthcare · Market cap HK$14.4B

0 0013 0013 · HK

PriceHK$16.78

Fair ValueHK$9.36

Upside-44.2%

Quality42/100

Evidence: Medium Range HK$5.41 – HK$17.24

Fair value as of: Jul 1, 2026

From 12 valuation models · updated today

Share price −8.4% over the past month.

Price vs Fair Value (12 months)

12‑month range HK$15.83 – HK$30.55 · fair‑value band HK$5.41 – HK$17.24 · the HK$16.78 price screens above the HK$9.36 fair value. As of Jul 1, 2026.

✦ Which stocks are undervalued right now? Check free Discover now →

Analysis

0013 (0013) currently trades at HK$16.78, while our model-based Fair Value estimate is HK$9.36 — implying the stock looks roughly 44.2% overvalued today. We read business quality at 42/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium — the entry price still matters most (evidence: medium).

Over the trailing twelve months, 0013 generated revenue of HK$549M at a net margin of 83.3%. Revenue declined 16.5% year over year. It earns a return on equity of 45.3%. Net debt stands at HK$26.6M. Fundamentals as of Jul 1, 2026

Key figures & financial health

Revenue (TTM) HK$549M

Revenue growth (YoY) -16.5%

Net margin 83.3%

Return on equity 45.3%

Free cash flow −HK$78.9M FY2025

P/E ratio 4.0

More key figures

Operating margin -13.2%

EPS (TTM) HK$0.5200

EPS growth (YoY) -98.1%

Net debt HK$26.6M FY2025

Figures from reported company fundamentals (EODHD) · as of Jul 1, 2026. TTM = trailing twelve months.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

0013 reported revenue of HK$549M in FY2025 versus HK$356M in FY2021, a compound +11.4%/yr. Reported net income was HK$457M in FY2025.

Revenue +11.4%/yr

FY21 HK$356M

FY22 HK$426M

FY23 HK$838M

FY24 HK$630M

FY25 HK$549M

Net income

FY21 −HK$195M

FY22 −HK$361M

FY23 HK$101M

FY24 HK$37.7M

FY25 HK$457M

Is 0013 fairly valued? → Check now

Similar stocks

6 more Drug Manufacturers - Specialty & Generic stocks, each showing price versus our Fair Value estimate (as of Jul 1, 2026).

Stock	Price	Fair Value	vs Fair Value
1276 1276	HK$57.85	HK$29.84	-48%
Jiangsu Hengrui Pharmaceuticals Co 600276	¥47.08	¥26.59	-44%
Sun Pharmaceutical Industries Limited SUNPHARMA	₹1,786	₹991.46	-44%
Zoetis Inc Z1TS34	R$25.93	R$19.70	-24%
Hansoh Pharmaceutical Group 3692	HK$29.30	HK$23.90	-18%
Divi's Laboratories Limited DIVISLAB	₹6,639	₹1,281	-81%

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks Technology Financial Services Healthcare Consumer Cyclical Consumer Defensive Communication Services Industrials Energy Basic Materials Real Estate Utilities Deeply Undervalued Stocks Undervalued Blue-Chip Stocks Undervalued Small-Cap Stocks

Frequently asked questions

Is 0013 (0013) undervalued?

As of Jul 1, 2026, our model estimates a fair value of HK$9.36 versus a price of HK$16.78 — about −44% (overvalued). Model-based estimate, not financial advice.

What is the fair value of 0013?

Our model-based fair value for 0013 is HK$9.36 (as of Jul 1, 2026), built from audited fundamentals. The current price is HK$16.78.

What is the quality score of 0013?

0013 has a Quality Score of 42/100, measuring profitability, growth and balance-sheet strength from non-valuation factors.

What is the revenue of 0013 (0013)?

0013 reported trailing-twelve-month revenue of about HK$549M (latest available figure, as of Jul 1, 2026).

What is the net profit margin of 0013?

The net profit margin of 0013 is about 83.3%, meaning it keeps roughly 83.3% of revenue as net income. Based on the latest reported figures.

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data — nothing guessed.

Educational research only · not financial advice · no buy/sell recommendation. Model-based estimates are not certainties; their reliability depends on data quality and assumptions.